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Protein inhibitor of activated STAT1 (PIAS1) func-
tions as a nuclear receptor coregulator and is expressed
in several cell types of human testis. However, the mech-
anism of PIAS1 coregulation is unknown. We report
here that PIAS1 has characteristics of a scaffold attach-
ment protein. PIAS1 localized in nuclei in a speckled
pattern and bound A-T-rich double-stranded DNA, a
function of scaffold attachment proteins in chromatin
regions of active transcription. DNA binding was de-
pendent on a 35-amino acid sequence conserved among
members of the PIAS family and in scaffold attachment
proteins. The PIAS family also bound the androgen re-
ceptor DNA binding domain, and binding required the
second zinc finger of this domain. PIAS1 contained an
intrinsic activation domain but had bi-directional ef-
fects on androgen receptor transactivation; lower ex-
pression levels inhibited and higher levels increased
transactivation in CV1 cells. Other PIAS family mem-
bers also had dose-dependent effects on transactivation,
but they were in a direction opposite to those of PIAS1.
When coexpressed with PIAS1, other PIAS family mem-
bers counteracted PIAS1 coregulation of androgen re-
ceptor transactivation. The interaction of PIAS1 with
other members of the PIAS family suggests a transcrip-
tion coregulatory mechanism involving a multicompo-
nent PIAS nuclear scaffold.
Androgen activation of the androgen receptor (AR)1 is essen-
tial for male sexual development and the initiation and main-
tenance of spermatogenesis (1–3). AR is a member of the ste-
roid receptor subgroup of the greater family of nuclear
receptors that function as transcription factors (4, 5). These
receptors have conserved DNA and ligand binding domains
that conform to similar three-dimensional structures (6–12),
whereas their N-terminal domains are characterized by
marked sequence variation (13, 14). Nuclear receptors bind
DNA as homo- or heterodimers (6, 15). AR homodimerization is
enhanced markedly in the presence of androgen-response ele-
ment (ARE) DNA and is required for formation of a stable
ARARE complex (16, 17). Dimerization of AR occurs through a
DNA binding domain interface and antiparallel interactions
between the N- and C-terminal domains (17, 18). Nuclear re-
ceptors regulate the transcription rate of RNA through inter-
actions with coactivators, corepressors, and the general tran-
scription machinery (19–24). Specific genes are regulated
through receptor interactions with coregulators and other chro-
matin remodeling factors (25–35) that control the accessibility
of nucleosomal DNA to the transcription complex.
Signal transducers and activators of transcription (STAT)
are so named because they serve as signal transducers in the
cytoplasm and as activators of gene transcription in the nu-
cleus. PIAS1 was isolated by Liu et al. (36) from a human
JY112 B cell cDNA library and by Tan et al. (37) from a HeLa
cell library using yeast two-hybrid screening for STAT1 and AR
interacting proteins, respectively. PIAS1 was shown to bind
STAT1 and inhibit STAT1 binding to its consensus response
element. PIAS1 inhibition of activated STAT1 signaling was
demonstrated in cotransfection assays with interferon -stim-
ulated 293 cells using a STAT1 reporter gene (36). In an earlier
study (37) we reported that PIAS1 is a transcriptional coacti-
vator with AR and GR but a repressor with progesterone re-
ceptor. PIAS1 is expressed predominantly in testis including
cell types that express AR and mediate the actions of androgen
on spermatogenesis. In addition to PIAS1 that inhibits STAT1,
another member of the PIAS family, PIAS3, has been shown to
be an inhibitor of STAT3 signaling. PIAS3 mRNA was also
abundant in human testis, but unlike PIAS1, it was expressed
at similar levels in other organs (38). Other known members of
the human PIAS family include PIASx, PIASx, and PIASy. A
mutant PIASx with deletion of amino acids 1–133 interacted
with a homeobox DNA-binding protein, Msx2. This mutant
protein, referred to as Miz1, had sequence-specific DNA bind-
ing activity and enhanced the DNA binding of Msx2 (36, 39).
PIASx (ARIP3) was also isolated as an AR-interacting protein
by two-hybrid screening of a mouse embryo library and was
found to be highly expressed in rat testis (40).
Here we report that PIAS family members have character-
istics of nuclear scaffold attachment factors (SAF). PIAS family
members were bi-directional transcriptional coregulators with
AR. In cells where there is expression of more than one family
member, our studies suggest that the coregulatory effects of
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PIAS1 are modulated by interactions with other members of
the PIAS family.
EXPERIMENTAL PROCEDURES
Plasmids—Full-length PIAS1 sense and antisense vectors and the
mutant PIAS1delF vector with deletion of amino acids 341–536 were
described previously by Tan et al. (37). Full-length PIASx, PIASx,
PIASy, and mouse PIAS3 (mPIAS3) were recovered from digestions of
pFLAG-PIASx, -x, -y, and mPIAS3 and cloned into pSG5 to create
pSG5-PIASx, -x, -y, and mPIAS3. pFLAG-PIAS vectors were pro-
vided by Ke Shuai, UCLA (36). BamHI-Klenow filled in fragments of
PIASx and -x derived from pSG-PIASx and -x were cloned into the
SmaI site of pBDGalCAM to create yeast Gal4 DNA binding domain
vectors, pBDGalCAM-PIASx and -x. The same fragments were
cloned into the filled in XhoI site of pGADGH to create yeast Gal4
activation domain vectors pGADGH-PIASx and -x. A specific probe
for PIAS1 was generated by PCR of pGADGH-PIAS1 (37) using 5
primer (GGTCTAGAGTCTTCCACATCAAGC) and 3 primer (CA-
GATCGAATGAACTTGGGAATTC). The PCR product was digested
with XbaI-EcoRI and cloned into the same sites of pBKCMV
(Stratagene).
Probes specific for PIASx and -x mRNAs were generated by PCR
with 5 primer (GCTCTAGAGCATGTCATCAGATTTGCCAGG) and 3
primer (CCACAACTAGAATGCAGTG) using pSG5-PIASx and -x as
templates. A probe specific for PIASy was generated by PCR with 5
primer (GCTCTAGAAGGAGCGCAGCTGCA) and 3 primer (CCA-
CAACTAGAATGCAGTG) with pSG5-PIASy as template. PCR products
were digested with XbaI-BglII and cloned into pBKCMV XbaI-BamHI
site. To create the vector pGBT-PIAS1 amino acids 7–651 of PIAS1
were excised with SmaI-XhoI and cloned into pGBT8. pGEX-PIAS1-(1–
135) and pGEX-PIAS1delSAP (1–166 del 11–45) were constructed by
PCR of templates pSG5-PIAS1 and pSG5-PIAS1delSAP with 5 primer
CTCTGAGTCCAAACCGGGCCCCTCTGC and 3 primer TCTC-
GAAAGCGCTGACTGTTGTCTGATGC. For cell-free binding assays
GST-PIAS1 (amino acids 7–651) was created by digesting pGADGH-
PIAS1 (37) with SpeI-XhoI and cloning the purified PIAS1 into the
XbaI-XhoI site of pGEX-KG. GST-AR (amino acids 544–634) was con-
structed by PCR of human pCMVhAR and cloning into pGEX-2T
BamHI-EcoRI sites. All constructs were confirmed by automatic se-
quencing using a Perkin Elmer model 377 DNA sequencer.
The probasin-luciferase reporter was provided by Dr. R. J. Matusik,
Department of Urologic Surgery, Vanderbilt University, and the pros-
tate-specific antigen-luciferase reporter by Dr. M. D. Sadar, British
Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Affinity Matrix Assay of PIAS1 Binding to A-T-rich DNA—GST fu-
sion proteins were expressed in Escherichia coli BL21 cells as de-
scribed (41). Scaffold attachment region-like A/T-rich oligonucleo-
tides (AATTCAGAAAATAATAAAATAAAACTAGCTATTTTATATTTT-
TTC and AATTGAAAAAATATAAAATAGCTAGTTTTATTTTATTATT-
TTCTG) were synthesized and annealed by heating to 70 °C and cooling
slowly to room temperature. Annealed oligonucleotide or E. coli DNA
was added in excess to glutathione-Sepharose-bound GST or GST-
PIAS1 proteins and incubated for 1 h at 4 °C. The mixture was washed
several times in 20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA,
0.5% Nonidet P-40, and 32P-labeled double-stranded oligonucleotide
(150,000 cpm) was added and the incubation continued for 1 h at 4 °C.
After several washes in the same buffer, the samples were counted in a
liquid scintillation counter.
Immunohistochemistry—COS7 cells were cultured in two chamber
glass slides and transfected with pSG5-PIAS1 as described earlier for
AR (42). Immunostaining was performed (43) using a polyclonal anti-
body raised in rabbit against a glutathione transferase-PIAS1 fusion
protein containing 102 C-terminal amino acids (549–650), provided by
J. Liao and K. Shuai, UCLA (37).
Yeast Liquid -Galactosidase Assay—Yeast Y190 cells were used for
the liquid -galactosidase assay. For assay of intrinsic transcriptional
activity of PIAS family members, Y190 yeast cells were transformed
with the Gal4 DNA binding domain vector (pBDGalCAM) containing
PIAS1, the PIAS1 mutant PIAS1delF, PIASx, or PIASx. For two-
hybrid protein-protein interactions of PIAS1 with PIASx or PIASx,
Y190 cells transformed with the pGBT-PIAS1 and the Gal4 activation
domain vector (pGADGH) containing PIASx or PIASx were incu-
bated at 30 °C in 2 ml of selective medium without Trp and Leu. In the
case of yeast transformed with the Gal4 DNA binding domain vector
alone, medium lacked only Trp and if transformed with the Gal4 acti-
vation domain vector alone lacked only Leu. After incubation for 20 h,
YPD medium (8 ml) was added, and incubations were continued for 3–4
h at the same temperature. The liquid -galactosidase assay was per-
formed according to the protocol of CLONTECH Laboratories Inc., Palo
Alto, CA.
Transient Cotransfection Assay—Cotransfection assays were per-
formed in triplicate as described (37). In brief, monkey kidney CV1 cells
were transfected with the mouse mammary tumor virus-long terminal
repeat-luciferase reporter vector, MMTV-luciferase (2.5 g), prostate-
specific antigen, PSA-luciferase (2.5 g) or probasin-luciferase reporter
(5 g), human androgen receptor (pSG5-hAR) 0.1 g, and various
amounts of pSG5 expression vectors containing PIAS cDNAs. To control
for possible DNA effects, CV1 cells were transfected with or without
equimolar amounts of the empty pSG5 vector, pSG5-PIAS1 antisense
vector, or pSG5-BTG1 that expresses the B cell translocation gene 1
(44). Cells were grown in 6-cm culture dishes and transfected by the
CaPO4 method when 70–80% confluent. After 15% glycerol shock for 4
min, the cells were incubated in Dulbecco’s modified Eagle’s medium-H
without phenol red and serum in the presence or absence of 0.1 nM
dihydrotestosterone (DHT) for 40 h. Cells were harvested in lysis buffer
(Ligand Pharmaceuticals Inc., San Diego, CA), and luciferase activity
was measured in a luminometer. Luciferase activity was expressed as
mean  S.D. light units of three replicates and as fold increase in the
presence of hormone over background in the absence of hormone. Assay
results in each figure are representative of three or more experiments.
In Situ Hybridization—pBKCMV-PIAS1, -x, -x, and -y were used
for in situ hybridization analysis. Antisense PIAS1-(1587–2101),
PIASx-(1628–1719), PIASx-(1628–1866), and PIASy-(1232–1533)
RNAs were synthesized and labeled with digoxigenin using the Roche
Molecular Biochemicals RNA labeling kit, and in situ hybridization of
mouse testis was performed as described (45).
AR Binding of 35S-PIAS Proteins—pSG5-PIAS1, -x, -x, and -y (36)
vectors were used as DNA templates for in vitro synthesis of labeled
protein by coupled in vitro transcription-translation. Glutathione S-
transferase (GST)-AR binding assays were performed as described (46).
In brief, the above cDNA vectors were incubated with [35S]methionine
and reticulocyte lysate from the TnT T7 Quick-coupled Transcription/
Translation System kit (Promega), and the labeled proteins were incu-
bated with GST-AR DNA binding domain (amino acids 544–634) glu-
tathione-Sepharose affinity matrix. After incubation and extensive
washes, labeled proteins were eluted by boiling in SDS buffer and
separated by SDS-PAGE, gel-dried, and exposed to Kodak x-ray film.
PIAS Protein Interaction—Recombinant PIAS family members syn-
thesized and labeled with [35S]methionine as described above were
incubated with GST-PIAS1 (amino acids 7–651) coupled to glutathione-
Sepharose. The gel was washed several times, and labeled proteins
were eluted and processed as above.
Northern Hybridization—Total RNA was extracted from testes of
rats at different ages by a modification of the method of Chirgwin et al.
(47) and Northern hybridizations performed as described (37) using the
DNA probes specific for PIAS1, PIASx, PIASx, and PIASy as indi-
cated above. Ribosomal RNA was stained with methylene blue to com-
pare the amounts of sample loaded in each lane. Sample loadings were
also checked by hybridization of 18 S rRNA. The cDNA for 18 S rRNA
was obtained from Ambion (Austin, TX) and labeled with 32P using a
random priming kit (Promega, Madison, WI).
RESULTS
PIAS Family Members Contain a Conserved Sequence Found
in Proteins That Bind Scaffold Attachment Region DNA—A
35-amino acid N-terminal sequence (aa 11–45) common to
PIAS family members and a number of other eukaryotic pro-
teins is referred to as the scaffold attachment factor, SAF box
(48), or SAF-A/B, Acinus, PIAS (SAP) domain (49). Secondary
structure modeling predicts the sequence forms two am-
phipathic helices (Fig. 1) with homology to helices 1 and 2 of
homeodomain proteins that are known to fold into a hook-like
structure with two -helices separated by a turn (48). Within
the conserved sequence is a bipartite distribution of hydropho-
bic and polar amino acids separated by a region that contains
an invariant glycine (49). In contrast to homeodomains that
contain three -helices and bind to strictly defined sequences in
the major groove of DNA, SAF box binding to DNA occurs
through a cooperative binding mode that recognizes scaffold
attachment region DNA through minor groove interactions
with multiple clustered adenine (A) tracts (48). In different
molecules the SAF box/SAP domain is linked to a diverse set of
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domains, several of which are known to be involved in
pre-mRNA processing (49).
PIAS1 Binds Double-stranded A-T-rich DNA—To learn
whether PIAS1 has the DNA binding properties of a scaffold
attachment region binding protein, we tested its binding to
A-T-rich DNA using an affinity matrix assay with the protein
attached to Sepharose beads (Fig. 2). GST or GST-PIAS1 (aa
1–135) were coupled to glutathione-Sepharose beads and incu-
bated with 32P-labeled A/T-rich oligonucleotide using a batch
method. Either unlabeled A-T-rich oligonucleotide or E. coli
DNA was used in competition with the 32P-labeled A-T-rich
oligonucleotide to demonstrate specific binding. It has been
demonstrated previously (48, 50, 51) that scaffold attachment
proteins do not bind E. coli DNA. Radioactive A-T-rich DNA
bound to GST-PIAS1-Sepharose was more than 300-fold higher
than that bound to the GST-Sepharose control, and binding
was inhibited by cold-A-T-rich DNA but not by E. coli DNA.
Deletion of the SAF box/SAP domain (GST-PIAS1 aa 1–166 del
11–45) abolished the binding to A-T-rich DNA demonstrating
the potential role of this domain in PIAS1 binding to scaffold
attachment region DNA.
PIAS1 Is Localized in Nuclei in a Punctate Distribution—
Immunostaining of PIAS1 transfected into COS cells revealed
a speckled pattern of localization in nuclei (Fig. 3) similar to
that of the scaffold attachment proteins SAF-B (52) and SAF-A
(heterogeneous nuclear ribonucleoprotein U) (53). Under the
microscope this same pattern of PIAS1 staining in nuclei could
be visualized in testis tissue sections by fine adjustment of
focusing, but the speckling was not apparent in photographs.
PIAS Family Members Have Negative and Positive Effects on
AR Transactivation—Coregulatory effects of the PIAS family
with DHT-dependent AR transactivation were analyzed in CV1
cell cotransfection assays with three different luciferase re-
porter genes, the mouse mammary tumor virus-long terminal
repeat (MMTV), the rat probasin gene 5-flanking region (nu-
cleotides 426 to 28), and the human prostate-specific anti-
gen gene (PSA) (nucleotides 630 to 12). With the MMTV-
Luc reporter gene PIAS1 had bi-directional effects on AR-
induced transcriptional activity (Fig. 4, top panel). At lower
amounts (0.01 and 0.05 g) transfected PIAS1 inhibited DHT-
dependent AR transactivation relative to equivalent amounts
of the antisense PIAS1 control. At a higher amount (0.5 g)
PIAS1 stimulated a 3-fold increase in DHT-dependent AR
transactivation. Similar results were obtained using the pro-
basin-Luc reporter gene (Fig. 4, middle panel). There was in-
hibition with 0.01 g of PIAS1 and enhancement with 0.5 g.
PIAS1 (0.5 g) also increased DHT-dependent AR transactiva-
tion of the PSA-Luc reporter above the level obtained with
equivalent amounts of pSG5PIAS1 antisense control vector or
the PIAS1delF mutant control that was shown previously (37)
to lack coactivator function (Fig. 4, bottom). We were unable to
test the inhibitory amounts of PIAS1 (0.01–0.1 g) with the
PSA-LUC reporter because of its lower responsiveness to AR-
induced transactivation.
PIASx, PIASx, and PIASy (0.5 g) each inhibited AR
induction of MMTV-Luc transcription relative to the pSG5
antisense control, whereas lower amounts (0.01 and 0.05 g)
were either less inhibitory than PIAS1 or had no effect (Fig. 4,
top panel). In assays with the probasin reporter gene (Fig. 4,
middle panel) PIASx, PIASx, and PIASy had either no effect
or were inhibitory (Fig. 4, middle panel). With the PSA reporter
gene PIASx, PIASx, and PIASy (0.5 g) were inhibitory (Fig.
4, bottom panel).
PIAS Proteins Interact Directly with AR in Vitro—In affinity
matrix assays full-length 35S-PIAS proteins bound glutathione
FIG. 1. PIAS family members contain an SAF box also referred
to as a SAP domain. Alignment of conserved sequences in PIAS1,
PIASx, PIASx, and PIASy amino acids 11–45 with those of SAF-A
(aa 8–42) and SAF-B (aa 31–65), two well characterized scaffold at-
tachment factors. Amphipathic helices within the SAF box sequence are
indicated by the enlarged regions (green) in a linear diagram at the top.
Highly conserved amino acids are in red.
FIG. 2. PIAS1 binds double-stranded A/T-rich DNA. Control
GST, GST-PIAS1 (aa 1–135), or GST-PIAS1 (aa 1–166 del 11–45),
indicated as dSAP, were coupled to glutathione-Sepharose beads and
incubated with 32P-labeled A/T-rich oligonucleotide using a batch
method. Either unlabeled A/T-rich oligonucleotide or E. coli DNA was
used in competition with the 32P-labeled A/T-rich oligonucleotide to
demonstrate specific binding. Beads were washed, and the radioactivity
was measured in a liquid scintillation counter. Error bars indicate 
S.D. of data from three independent experiments.
FIG. 3. Localization of PIAS1 in nuclei. COS cells cultured on
two-chamber microscope slides were transfected with pSG5PIAS1 and
incubated for 40 h. Cells were fixed and immunostained for PIAS1 as
described under “Experimental Procedures.” PIAS1 is indicated by
brownish staining clustered in dense foci to produce a stippled pattern.
Nuclei of several non-transfected cells can be seen in the same field of
view.
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S-transferase (GST) AR (amino acids 544–634). This region of
AR includes the entire DNA binding domain and small portions
of the N-terminal and hinge regions (14). Each of the proteins
PIAS1, PIASx, PIASx, or PIASy bound the AR DNA binding
domain region (Fig. 5A) suggesting they interact with AR by
similar mechanisms. From previous studies we concluded that
a sequence within PIAS1 amino acids 1–318 is required for
AR binding; however, the precise binding motif remains to be
identified (37).
Because the 2nd zinc finger has been implicated in steroid
receptor protein-protein interactions, we tested the binding of
PIAS1 to the AR DNA binding domain fragment (amino acids
544–634) from which the 2nd zinc finger was deleted. Deletion
of the 2nd zinc finger (amino acids 589–627 encoded by AR
gene exon 3) resulted in a major decrease in PIAS1 binding
relative to its binding to the wild-type AR (Fig. 5B).
PIAS1 Has an Intrinsic Activation Function in Yeast Greater
Than That of PIASx or -x—Because PIAS1 stimulated AR
transactivation to a greater extent than PIASx or PIASx, we
compared their intrinsic activation functions in Y190 yeast
cells using the Gal DNA binding domain vector (pBDGalCAM)
containing PIAS1, PIASx, PIASx, or the PIAS1 mutant
PIAS1delF (Fig. 6). In liquid -galactosidase assays PIAS1 had
intrinsic transcriptional activity that was 7 times greater than
that of PIASx. PIASx had no activity and there was barely
detectable activity with PIAS1delF. Thus the relative intrinsic
activation functions of these proteins in yeast are reflective of
their coregulator effects in the CV-1 cell cotransfection assay
with PIAS1 being the only coactivator member of the family in
this system.
Expression of PIAS1, PIASx, PIASx, and PIASy Genes in
Testis—We reported earlier (37) that PIAS1 mRNA is ex-
pressed at a relatively high level in human testis, and PIAS1
protein is localized by immunohistochemical staining in nuclei
of androgen/AR-regulated peritubular myoid cells and Sertoli
cells. In addition there was staining of developing germ cells
throughout the seminiferous tubular epithelium. Similar dis-
tribution of PIASx protein in mouse testis (referred to as
ARIP3) was reported by Moilanen et al. (40). To localize the
expression of other PIAS genes in testis, we performed in situ
hybridization using specific probes for PIAS1, PIASx, PIASx,
and PIASy mRNAs based on sequences reported by Liu et al.
(36) (Fig. 7). In the sexually mature mouse, there was staining
of PIAS1 and other family members in cytoplasm throughout
FIG. 4. Coregulatory effects of PIAS proteins on AR transacti-
vation. The AR expression vector pSG5hAR (0.1 g) and a reporter
vector (2.5 g) were cotransfected into CV1 cells in 6-cm dishes with
different amounts of pSG5-PIAS1 antisense vector (37) to balance the
DNA or pSG5-PIAS expression vector as indicated at the bottom of each
bar: 1, control (C) pSG5-AR 0.1 g  reporter 2.5 g; 2, control  0.01
g of the indicated expression vector; 3, control  0.05 g of the vector;
4, control  0.5 g of the vector. Cells were incubated in the absence (on
the left of each solid bar) and presence (solid bars) of 0.1 nM dihydrotes-
tosterone. The PIAS expression vectors were pSG5PIAS1,
pSG5PIAS1delF (full-length PIAS1 with deletion of amino acids 341–
537) (37), pSG5PIASx, pSG5PIASx, and pSG5PIASy. The reporter
vectors are as follows: top, mouse mammary tumor virus (MMTV)-
luciferase; middle, probasin-luciferase; bottom, PSA-luciferase. Assays
were performed in triplicate, and error bars represent  S.D.
FIG. 5. PIAS family members bind the AR DNA binding do-
main. A, binding of full-length [35S]methionine-labeled PIAS proteins
(indicated at the top of the figure) to GST-AR DNA binding domain (AR
amino acids 544–634). Lane 1, input of 35S-PIAS protein (10%); lane 2,
GST control; lane 3, 35S-PIAS binding to GST-AR DNA binding domain.
B, absence of binding of PIAS proteins to a mutant AR DNA binding
domain with deletion of 2nd zinc finger amino acids 589–627 as a result
of an AR gene exon 3 deletion: C is GST control; del589–627 is the
AR-DNA binding domain with deletion of 2nd zinc finger, and 544–634
is the wild-type AR DNA binding domain.
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the germinal epithelium, but regional differences in the inten-
sity of staining were noted. PIAS1 staining was darker near the
central region associated with round spermatids. In contrast,
there was more PIASx in the peripheral layers of cells that
appeared to include Sertoli cells, spermatogonia, and early
spermatocytes. PIASx was similar to PIASx but was less
intense and tended to be more evenly distributed throughout
the germinal epithelium. PIASy mRNA staining was somewhat
darker in the mid-region of the epithelium. Variable staining
among different tubules suggested the expression of PIAS
genes is dependent on the stage of spermatogenesis.
In the 3-day-old mouse testis there was little or no staining
of mRNAs for PIAS1, PIASx (Fig. 7, bottom panel), PIASx, or
PIASy (not shown). However, by 12 days of age all family
members were detected with PIAS1  PIASx  PIASy 
PIASx (not shown).
In rat testis the different PIAS family members were ex-
pressed similarly during development although PIASx and
PIASy appeared somewhat earlier than did PIASx or PIAS1
as shown by Northern hybridization of total RNA using specific
probes (Fig. 8). mRNA levels were detected in prepubertal rats
and increased in intensity with age consistent with expression
in Sertoli cells as well as spermatogenic cells.
It was reported recently by Schlegel et al. (54) that PIASx
mRNA was not detected in mouse and rat Leydig cells and
Sertoli cells isolated by centrifugal elutriation but only in sper-
matogonia, primary spermatocytes, and round spermatids.
Moreover PIASx mRNA, although present in testes of men
with normal spermatogenesis, was not detected in infertile
men with the Sertoli cell only syndrome. We did not detect
PIASx by Northern hybridizations of total RNA from cultured
Sertoli cells of 18-day-old rats, although under the same con-
ditions PIAS x mRNA was abundant and PIASy was a weaker
band (results not shown). However, this difference may reflect
the immaturity of the cultured Sertoli cells. As shown in the
above developmental study in rat testis (Fig. 8), at 16 and 20
days of age PIASx and PIASy mRNAs were more abundant
than PIASx.
Coregulatory Effects of PIAS1 on AR Are Modulated by Co-
expression of PIASx, PIASx, or PIASy—Because some mem-
bers of the PIAS family are coexpressed in AR-regulated cells of
testis, we asked if the bidirectional regulatory effects of PIAS1
on AR transactivation were altered by coexpression with other
proteins of the PIAS family (Fig. 9). Cotransfection assays were
performed in CV1 cells using pSG5hAR and MMTV-luciferase.
In the presence of a low amount of transfected PIAS1 (0.05 g),
DHT-dependent AR-induced luciferase activity was markedly
inhibited. This inhibition by PIAS1 was attenuated by cotrans-
fection of an equal amount (0.05 g) of PIASx, PIASx, or
FIG. 6. Intrinsic activation functions of PIAS1 and PIASx. The
Gal DNA binding domain vector pBD-GalCAM containing either full-
length PIAS1, PIASx, PIASx, or a PIAS1 mutant with deletion of
amino acids 341–537 (PIAS1delF) was used to transform yeast Y190.
Yeast were plated and colonies were picked on selective medium lacking
Trp. -Galactosidase (-gal) units were determined in a liquid assay
using the substrate o-nitrophenyl -D-galactopyranoside. Relative -ga-
lactosidase activity represents units measured above the empty vector
background.
FIG. 7. Expression of PIAS genes in mouse testis. In situ hybrid-
ization of PIAS mRNA in adult mouse testis was performed using
probes specific for the different family members, PIAS1 (nucleotides
1587–2101), PIASx-(1628–1719), PIASx-(1628–1866), and PIASy-
(1232–1533). In the two bottom panels are in situ hybridizations of
3-day-old mouse testis with PIAS1 and PIASx. PIASx and PIASy
were also negative in 3-day-old mouse testis.
FIG. 8. Age-dependent expression of PIAS mRNA in rat testis.
Northern hybridization of PIAS mRNAs from rat testis during sexual
development was performed as described (37). Total RNA (10 g per
lane) was isolated from rat testes at the ages indicated and hybridized
with 32P-PIAS probes containing sequences specific for the different
family members as shown in Fig. 7. RNA sample loadings are indicated
by a representative hybridization of 18 S rRNA shown at the bottom.
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PIASy but was not influenced by cotransfection of the same
amount of control vector DNA (Fig. 9, top panel). Thus coex-
pression of other PIAS family members counteracted the low
dose inhibitory effect of PIAS1 on AR transactivation.
Similarly, the stimulation of AR transactivation by cotrans-
fection with a 10-fold larger amount of PIAS1 (0.5 g) was
offset by cotransfection of an equal amount (0.5 g) of PIASx,
PIASx, or PIASy. Luciferase levels obtained with each of
these family members in combination with PIAS1 approached
the levels obtained with PIASx, PIASx, or PIASy alone. In
contrast, when 0.5 g PIAS1 was cotransfected with an equal
amount of the same vector, PIAS1 (0.5 g), luciferase activity
was unchanged (Fig. 9, middle panel).
The dose-response effect of PIAS1 on DHT-dependent AR
transactivation was quite different from PIASx, PIASx, or
PIASy in this system. With the PIAS1 there was inhibition of
AR transactivation at the lower doses of expression vector
(0.025–0.1 g) and a steep transition to stimulation of trans-
activation between 0.1 and 0.25 g. On the other hand PIASx,
PIASx, and PIASy caused either slight stimulation or had no
effect at the lower doses and were inhibitory at the higher doses
(Fig. 9, bottom panel).
PIAS1 Interacts Directly with Other Members of the PIAS
Family—Protein-protein interactions of PIAS1 with PIASx
and PIASx were analyzed in the yeast two-hybrid system.
Y190 yeast cells were transformed with pGBT-PIAS1, that
expresses a Gal DNA binding domain-PIAS1 fusion protein
together with the vector pGADGH that expresses the Gal ac-
tivation domain fused to either PIASx or PIASx. Cells were
incubated overnight at 30 °C in selective medium, and -galac-
tosidase activity was measured in the liquid assay (37) (Fig.
10). The -galactosidase activity of PIAS1  PIASx was 4–6-
fold higher than with either vector alone. Similarly the activity
with PIAS1  PIASx was 3–4-fold higher than either PIAS1
or PIASx alone indicating that PIAS1 interacts with PIASx
and PIASx.
Binding was also examined in affinity matrix assays using
GST-PIAS1 (aa 7–651) coupled to glutathione-Sepharose and
recombinant 35S-PIAS proteins synthesized in vitro (Fig. 11).
In these assays 35S-PIAS1, PIASx, PIASx and PIASy each
bound to GST-PIAS1, whereas binding to GST-glutathione-
Sepharose was negligible. The results indicated that PIAS1 can
FIG. 9. AR coregulator effects of PIAS1 are modulated by PI-
ASx, PIASx, or PIASy. AR expression vector pSG5hAR (0.1 g) and
reporter vector MMTV-Luciferase (2.5 g) were cotransfected into CV1
cells in 6-cm dishes, and the effect of PIAS1 on AR transactivation was
tested in combination with PIASx, PIASx, or PIASy. Cells were incu-
bated in the absence (shown on the left of each solid bar) or presence (solid
bars) of 0.1 nM dihydrotestosterone. Top panel, the lower amount of PIAS1
transfected (0.05 g) inhibited AR transactivation. PIAS1 (indicated by 
sign) inhibition was attenuated by cotransfection with 0.05 g of PIASx,
PIASx, or PIASy. DNA was balanced with equimolar amounts of pSG5
empty vector or pSG5-BTG1. Neither vector alone inhibited AR transac-
tivation. Middle panel, cells were transfected with pSG5hAR, MMTV-
luciferase, and pSG5PIAS vectors as above. The 10-fold higher amount of
PIAS1 (0.5 g) increased AR transactivation, whereas equal amounts of
PIASx, PIASx, or PIASy reduced or caused no change in AR transac-
tivation (shown on the left side of panel). The PIAS1-induced increase in
luciferase units was not changed by cotransfection of an additional 0.5 g
of PIAS1 but was inhibited by 0.5 g of PIASx, PIASx, or PIASy (shown
on the right). Bottom panel, dose-response curves for antisense PIAS1,
PIAS1, PIASx, PIASx, and PIASy. Assays were performed as above
with transfections of increasing amounts of pSG5 expression vector DNA
(indicated by numbers 1–6); C (control), pSG5AR  MMTV-luciferase
alone; 1, control  0.025 g; 2, control  0.05 g; 3, control  0.075 g; 4,
control  0.1 g; 5, control  0.25 g; and 6, control  0.5 g. The points
represent activity measured in the presence of 0.1 nM dihydrotestoster-
one. Assays were performed in triplicate, and error bars represent  S.D.
FIG. 10. Binding of PIAS1 to PIASx and PIASx in a yeast
two-hybrid assay. PIAS1 was cloned into the Gal DNA binding do-
main vector, pGBT8. PIASx and PIASx were cloned into the Gal
activation domain vector, pGADGH. Y190 yeast were transformed with
the individual vectors and with combinations of PIAS1  PIASx and
PIAS1  PIAS x. The yeast liquid -galactosidase (-gal) assay was
performed as described under “Experimental Procedures.”
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self-associate or form multimers with other members of the
PIAS family.
DISCUSSION
In earlier studies (37) we found that PIAS1 is a nuclear
receptor coregulator that increases transcriptional activity of
the ligand-activated AR. Different regulatory functions have
been reported for PIAS proteins as we discuss below; however,
a common mechanism to explain these multiple actions has not
yet been identified. Herein we report that PIAS1 has charac-
teristics of a scaffold/matrix attachment region binding protein
(48, 55). It contains a SAF box or SAP domain conserved in this
family of proteins (48, 49) and binds double-stranded A-T-rich
DNA. Like other S/MAR-binding proteins such as SAF-A (51,
53) and SAF-B (50, 52, 56), PIAS1 was localized in nuclei in
clusters that formed a speckled pattern. S/MAR binding scaf-
fold attachment factors SAF-A, also known as heterogeneous
nuclear ribonucleoprotein U (53), and SAF-B (50, 56) have been
reported to interact with steroid receptors. SAF-B bound the
estrogen receptor and in transient transfection assays inhib-
ited estrogen receptor transactivation in a dose-dependent
manner (57). Similarly, SAF-A inhibited transactivation of the
glucocorticoid receptor (53, 58). Binding of both SAF proteins
involved the receptor DNA binding domain and hinge regions.
SAF-A and SAF-B are ubiquitous, abundant nuclear proteins.
SAF-B colocalizes and interacts with a subset of serine/argi-
nine-rich processing factors. It binds also to RNA polymerase II
and may serve as an assembly point for the formation of a
“transcriptosomal” complex (52). Whereas steroid receptor
transactivation was inhibited by overexpression of SAF-A in
transient transfection assays, it was suggested that this may
have resulted from a change in the receptor to SAF-A ratio,
which converted a positive into a negative effect on transcrip-
tion (53).
An additional finding in our study was that PIAS1 had a
striking concentration-dependent biphasic effect on AR trans-
activation. At lower expression levels in CV1 cells it inhibited
but at higher levels it enhanced AR transactivation. In an
earlier report (37) we demonstrated that at a still higher con-
centration PIAS1 coactivation was reduced. This biphasic effect
of concentration was similar to the effect on signaling observed
with a kinase scaffold protein. In signaling through a scaffold
too much or too little of any component may decrease the
output of the pathway (59). PIAS1 contains a RING-finger like
domain (amino acids 325–382) (36, 37, 60) that is conserved
among members of the PIAS family (36). It has been proposed
that RING domains can self-assemble into macromolecular
scaffolds that attach other regulatory molecules (61). Self-as-
sociation of PIAS1 would be consistent with its speckled pat-
tern of localization in nuclei.
In contrast to PIAS1, other members of the PIAS family,
PIASx, PIASx, or PIASy at lower expression levels in CV1
cells had smaller coregulator effects on AR transactivation that
were somewhat variable but at higher levels inhibited AR
transactivation. Thus with this assay system there are distinct
differences in AR coregulatory effects within the PIAS family.
Whether these differences relate to different scaffold properties
or to other functions remains to be determined.
Because some PIAS family members are coexpressed with
AR in androgen-regulated cells of the seminiferous tubules,
there is a potential for interactions between AR and the differ-
ent PIAS proteins. In CV-1 cell assays PIASx, PIASx, and
PIASy counteracted the effects of PIAS1 on AR transactivation,
both the inhibition at lower PIAS1 levels and the enhancement
at higher levels were partially reversed. The direct interaction
of PIAS family members with PIAS1 in yeast and in cell-free
assays indicated that coregulator functions of PIAS1 can be
modulated by formation of heteromers with other members of
the PIAS family. Androgen-activated AR has a strong tendency
to form homodimers in the presence of androgen-response ele-
ment DNA (16) making it likely that PIAS proteins interact
with AR homodimers in nuclei. Our results suggest that PIAS1
can form multimers through self-association or with other
PIAS family members. This ability of PIAS family members to
associate may relate to the self-assembly properties of their
RING domains and suggests that they can form scaffolds con-
taining the different family members.
Kotaja et al. (62) reported that the coregulatory effects PI-
ASx, referred to as androgen receptor interacting protein 3
(ARIP3), PIASx, and PIAS3 are influenced by cell type and
the reporter gene enhancer/promoter in transient cotransfec-
tion assays. By using a simple ARE2TATA-LUC reporter, PI-
ASx was a coactivator with AR in HepG2 cells, and the coac-
tivator activity was stronger in HepG2 cells than in HeLa cells.
However, with the more complex probasin gene enhancer/pro-
moter, PIASx was a repressor of AR transactivation in HeLa
cells, and with this same reporter gene in HepG2 cells PIASx
had little effect. Their results suggest that other cellar factors
can have a major influence on PIAS coregulation.
In previous studies (37) we demonstrated it is the N-terminal
region of PIAS1 that mediates androgen-dependent binding to
the AR DNA binding domain and among the PIAS family there
is sequence similarity that would suggest a common N-termi-
nal site for AR interaction. N termini of PIAS family members
contain an LXXLL motif (amino acids 19–23) (36, 37). LXXLL
motifs of p160 coregulators interact with activation function 2
domains (63–65) in the C-terminal region of nuclear receptors.
However, in AR the hydrophobic cleft within the C-terminal
region that forms activation function 2 is the interaction site
for the N/C interaction mediated by a FXXLF motif in the AR
N terminus (41, 66). The AR N-terminal region binds p160
coactivators independent of LXXLL motifs (67, 68). At present
we have no evidence that LXXLL motifs of PIAS family mem-
bers are involved in PIAS binding to the AR.
Gross et al. (69) reported that the LXXLL motif in PIASy is
required for suppression of AR transactivation but not for
PIASy binding to the AR DBD. More recently Liu et al. (70)
observed that PIASy bound activated STAT1 and inhibited
transcriptional activation of a STAT1 reporter gene without
affecting STAT1 binding to DNA. The LXXLL motif was re-
quired for PIASy inhibition of transcription but not for PIASy
binding to STAT1. On the basis of these results it was sug-
gested that the LXXLL motif enables PIASy to function as an
adaptor protein to link STAT1 to a transcriptional corepressor.
In our experiments with PIAS1, mutating the LXXLL motif to
LXXAA altered the dose-response curve with AR but did not
abolish either the corepression at low doses or coactivation at
higher doses (data not shown).
Whereas PIAS1 inhibited the binding of activated STAT1 to
its DNA-response element (36, 71), PIAS1 does not likely in-
FIG. 11. Binding of PIAS1 to itself and to other PIAS family
members in an affinity matrix assay. [35S]Methionine-labeled PIAS
proteins were synthesized in vitro and incubated with GST-PIAS1
coupled to glutathione-Sepharose (lane 3) or with the control GST-
glutathione Sepharose (lane 2). Assays were performed as described
under “Experimental Procedures.” Input (lane 1) was 10% of radioac-
tivity loaded.
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hibit AR binding to androgen-response element DNA under
conditions where it acts as a coactivator. PIAS1 enhancement
of AR transcriptional activation requires DNA binding to an-
drogen-response element DNA and is abolished by mutations
in the AR DNA binding domain (1, 2, 72). Involvement of the
AR second zinc finger motif in AR binding of PIAS proteins is of
interest because it was predicted earlier that the nuclear re-
ceptor DNA binding domain is a site of interaction with regu-
latory proteins (6, 73) and has functional surfaces for protein
interactions (74). Several regulatory factors interact directly
with the DNA binding domain or DNA binding domain and
hinge region of AR and other nuclear regulatory proteins (40,
75–81).
The intrinsic transcriptional activity of PIAS1 and to a lesser
extent PIASx suggests they contain an activation function
resulting from enzyme activity or binding to another coregula-
tor. Our assays in yeast were in agreement with the results of
Kotaja et al. (62) in HeLa cells and HepG2 cells in that intrinsic
transcriptional activity of PIAS1 was greater than that of PI-
ASx. In PIAS1 this activation function was dependent on a
sequence within amino acids 341–536, the region deleted in the
nonfunctional mutant PIAS1delF (37). Within the activation
function domain (aa 341–536) are cysteine residues predicted
to form a RING-finger like domain described above and an
acidic domain (36, 37, 60). The RING finger-like sequence is
conserved in the PIAS family (36). However, in the C-terminal
half of the activation domain there is sequence variation that
could account for the different AR coregulator activities of PIAS
family members.
As scaffold attachment factors PIAS family members may
control the regulatory functions of numerous proteins and me-
diate cross-talk between different signaling pathways. For ex-
ample, when activated STAT1 binds to response element DNA
it recruits CBP/p300 (82). Thus PIAS1 binding of STAT1 (71)
might prevent STAT1 recruitment of CBP/p300 thereby mak-
ing CBP/p300 more available for binding to other transcription
factors. Precedent for this idea was reported with -interferon
and JAK/STAT signaling during macrophage development
(83). On the other hand, binding of PIAS1 by nuclear receptors
(37, 76) or other proteins could increase activated STAT1 sig-
naling by removing PIAS1 inhibition. STAT3 signaling was
enhanced by PIAS3 binding to the zinc finger protein Gfi-1 (84).
Similarly, AR transactivation was positively regulated by PI-
ASx binding to the nuclear protein DJ-1 (85). Binding to DJ-1
counteracted PIASx inhibition of AR transactivation.
An increasing number of PIAS interactions with other pro-
teins are being identified. Originally PIAS1 was referred to as
the Gu-binding protein (86), in that it bound Gu RNA helicase
II. The Gu-binding protein was localized throughout the nucle-
oplasm, whereas Gu RNA helicase was confined to nucleoli
(87). Although the full significance of Gu RNA helicase II
binding remains to be determined, ATP-dependent helicases
are involved in a variety of transcription-related processes (see
Ref. 37 and references therein).
PIAS1 also has sequence similarity to a K channel-associ-
ated protein, KChAP (88), and PIAS3 has even greater homol-
ogy with KChAP (89). Although KChAP localizes in nuclei
(88–90), it interacts with both  and  subunits of K channels,
and when expressed in Xenopus oocytes, it increases the
amounts of specific K channel  subunit proteins at the cell
surface.
The mouse homologue of PIASx (mDIP) binds the p67 iso-
form of mouse disabled 2 (mDab2) (91). mDab2, especially the
p67 isoform, is highly expressed in differentiating murine F9
embryonal carcinoma cells following treatment with retinoic
acid. The N-terminal phosphotyrosine interacting domain of
mDab2 interacts with the C-terminal region of mDIP.
In Drosophila melanogaster, homologues of PIAS proteins
are expressed by alternative splicing from the zimp gene, which
is an allele of Suppressor of Position-Effect Variegation SU-
(var)2-10 (92). SU(var)2-10 proteins colocalize with nuclear
lamin in interphase and are present in some polytene chromo-
some telomeres. SU(var)2-10 is essential for embryo develop-
ment. The SAP domain may link specific chromosome regions
to the nuclear lamina. One model holds that SU(var)2-10 pro-
tein isoforms function in a variety of transcription regulation
complexes together with chromosome-bound transcription fac-
tors controlling different cellular responses (93).
PIAS family members can function as E3 ligases for small
ubiquitin-related modifier (SUMO) conjugation. E3 ligase ac-
tivity resides in the RING-related motif. Yeast E3-like factors
Siz 1 and Siz 2 have homology with the RING motif of PIAS
(94). PIAS1 was reported to bind p53 as well as the ubiquitin
carrier protein ligase Ubc9 and to promote SUMO conjugation
of p53 (60). PIASy was also an E3 ligase for the transcription
factor, lymphoid enhancer factor 1 (LEF1), a nuclear mediator
of Wnt signaling. PIASy repressed LEF1 induced transcription
and sequestered LEF1 in nuclear bodies. The targeting to nu-
clear bodies was dependent on the RING domain of PIASy.
However, PIASY-mediated localization of LEF1 in nuclear bod-
ies appeared to be independent of LEF1 sumoylation because it
was unaffected by a mutation in the LEF1 SUMO conjugation
site (95). Neither did this mutation interfere with PIASy inhi-
bition of LEF1 transactivation. Thus the mechanism of PIASy
inhibition remains to be established. One possibility is that
PIASy promoted the sumoylation of other coregulators that
repressed LEF1 transactivation and subnuclear sequestration
(95). Another possibility would relate these effects more to the
self-assembly properties (61) and scaffold functions of RING
domain proteins.
The binding of PIAS family members to A-T-rich DNA in
regions of active transcription, the presence of RING domains
with E3 ligase activity, and the potential to form nuclear scaf-
folds for attachment of regulatory proteins provide a basis for
understanding the multifunctional nature of PIAS. Expression
of PIAS in androgen-regulated peritubular myoid cells, Sertoli
cells, and in spermatogenic cells throughout the germinal epi-
thelium indicates this family of interactive coregulators is in-
volved in controlling multiple stages of germ cell development.
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52. Nayler, O., Strãtling, W., Bourquin, J.-P., Stagljar, I., Lindemann, L., Jasper,
H., Hartmann, A. M., Fackelmayer, F. O., Ullrich, A., and Stamm, S. (1998)
Nucleic Acids Res. 26, 3542–3549
53. Eggert, M., Michel, J., Schneider, S., Bornfleth, H., Baniahmad, A.,
Fackelmayer, F. O., Schmidt, S., and Renkawitz, R. (1997) J. Biol. Chem.
272, 28471–28478
54. Schlegel, P. N., Mielnik, A., Chan, P. T., and Morris, P. L. (2001) Program of
the 83rd Annual Meeting of the Endocrine Society, June 20-23, Denver, Co.,
pp. 401 (Abstr. P2–498)
55. Bode, J., Benham, C., Knopp, A., and Mielke, C. (2000) Crit. Rev. Eukaryotic
Gene Expr. 10, 73–90
56. Oesterreich, S., Lee, A. V., Sullivan, T. M., Samuel, S. K., Davie, J. R., and
Fuqua, S. A. W. (1997) J. Cell. Biochem. 67, 275–286
57. Oesterreich, S., Zhang, Q., Hopp, T., Fuqua, S. A. W., Michaelis, M., Zhao,
H. H., Davie, J. R., Osborne, C. K., and Lee, A. V. (2000) Mol. Endocrinol.
14, 369–381
58. Tang, Y., Getzenberg, R. H., Vietmeie, B. N., Stallcup, M. R., Eggert, M.,
Renkawitz, R., and DeFranco, D. B. (1998) Mol. Endocrinol. 12, 1420–1431
59. Ferrell, J. E. (2000) Science’s stke, www.stke.org/cgi/content/full/OC_sigtrans;
2000/52/pe1
60. Kahyo, T., Nishida, T., and Yasuda, H. (2001) Mol. Cell 8, 713–718
61. Kentsis, A., Gordon, R. E., and Borden, K. L. B. (2002) Proc. Natl. Acad. Sci.
U. S. A. 99, 667–672
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